Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Diagnostic sequencing identifies high-risk markers + resistance mechanisms (Cereblon pathway alterations in 24.3% of IMiD-treated patients, del 4p (CD38) in patients post-anti-CD38, BCMA deletions and mutations in patients treated with anti-BCMA.”
Title: Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.
Authors: Parvathi Sudha, Phillip Pham, Wen Niu, Enze Liu, Lin Wang, Gillian Truong, Cameron Ligocki, Ramzi Al-Azzawi, Mallini Surapenini, Steven Bray, Francesco Vetrini, Magdalena Czader, Marwan Tayeh, Kelvin P Lee, Rafat Abonour, Attaya Suvannasankha, Brian A Walker
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski on OncoDaily.
